Prelude Therapeutics (PRLD) Interest Expenses (2019 - 2026)
Prelude Therapeutics (PRLD) posted Interest Expenses of $20.3 million for Q1 2026, up 2661.17% sequentially from $734000.0 in Q4 2025, and down 11.66% YoY from $22.9 million in Q1 2025.
Prelude Therapeutics (PRLD) Interest Expenses (2019 - 2026) Analysis & Trends
Prelude Therapeutics has reported Interest Expenses for 8 years, with the latest figure at $20.3 million in Q1 2026.
- Quarterly Interest Expenses fell 11.66% year-over-year to $20.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.3 million (down 11.66% YoY) and the FY2025 annual result came in at $211.9 million, up 16.02% from the prior year.
- Interest Expenses climbed to $20.3 million in Q1 2026 per PRLD's latest filing, from $734000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $111.1 million in Q4 2022 and troughed at $482000.0 in Q4 2023.
- A 5-year average of $22.1 million and a median of $12.1 million in 2022 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2023 and 2024: Interest Expenses sank 99.57% in 2023, then soared 1519.46% in 2024.
- Over 5 years, Interest Expenses stood at $111.1 million in 2022, then tumbled by 99.57% to $482000.0 in 2023, then increased by 10.37% to $532000.0 in 2024, then soared by 37.97% to $734000.0 in 2025, then surged by 2661.17% to $20.3 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $20.3 million, $734000.0, and $21.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Prelude Therapeutics | 442.91 Mn | 162.28 Mn | - | 37.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.25 Mn |
| Jun 30, 2026 | 37.25 Mn |
| Mar 31, 2026 | 20.27 Mn |
| Mar 31, 2026 | 20.27 Mn |
| Dec 31, 2025 | 734,000.00 |
| Dec 31, 2025 | 734,000.00 |
| Sep 30, 2025 | 21.60 Mn |
| Sep 30, 2025 | 21.60 Mn |
| Jun 30, 2025 | 22.27 Mn |
| Jun 30, 2025 | 22.27 Mn |
| Mar 31, 2025 | 22.94 Mn |
| Mar 31, 2025 | 22.94 Mn |
| Dec 31, 2024 | 532,000.00 |
| Dec 31, 2024 | 532,000.00 |
| Sep 30, 2024 | 42.11 Mn |
| Sep 30, 2024 | 42.11 Mn |
| Jun 30, 2024 | 42.69 Mn |
| Jun 30, 2024 | 42.69 Mn |
| Mar 31, 2024 | 43.29 Mn |
| Mar 31, 2024 | 43.29 Mn |